Daiwa Securities Group
ALNY icon

Daiwa Securities Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Daiwa Securities Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-100
Closed -$93K – 1314
2022
Q3 		$93K Buy
+100
New +$19.1K ﹤0.01% 1008

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Daiwa Securities Group's ALNY Position: Q1 2026 in Review

Daiwa Securities Group reduced its Alnylam Pharmaceuticals (ALNY) stake by 2.4% in Q1 2026, selling an estimated $216K and leaving 25,364 shares worth $8.39M. The position accounts for 0.02% of the portfolio, ranked #358.

Daiwa Securities Group first reported a position in ALNY in Q2 2015 and has held it in 40 quarters since. The position peaked at $10.3M in Q4 2025. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Daiwa Securities Group held 25,364 shares of Alnylam Pharmaceuticals worth $8.39M as of Q1 2026.
  • Daiwa Securities Group sold 635 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $216K.
  • Alnylam Pharmaceuticals made up 0.02% of Daiwa Securities Group's portfolio in Q1 2026, its #358 holding.
  • Daiwa Securities Group first reported a position in Alnylam Pharmaceuticals in Q2 2015 and has held it in 40 quarters since.
  • Daiwa Securities Group's Alnylam Pharmaceuticals position peaked at $10.3M in Q4 2025.
  • 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.